A more powerful test for three-arm non-inferiority via risk difference: Frequentist and Bayesian approaches.

ABSTRACT: Necessity for finding improved intervention in many legacy therapeutic areas are of high priority. This has the potential to decrease the expense of medical care and poor outcomes for many patients. Typically, clinical efficacy is the primary evaluating criteria to measure any beneficial effect of a treatment. Albeit, there could be situations when several other factors (e.g. side-effects, cost-burden, less debilitating, less intensive, etc.) which can permit some slightly less efficacious treatment options favorable to a subgroup of patients. This often leads to non-inferiority (NI) testing. NI trials may or may not include a placebo arm due to ethical reasons. However, when included, the resulting three-arm trial is more prudent since it requires less stringent assumptions compared to a

SUBMITTER: Paul E 

PROVIDER: S-EPMC10013311 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature